Improving immunotherapy response through the use of designer bacteria

Area of Science:

• Cancer research
• Immunotherapy
• Synthetic biology
• Microbiome engineering

Background:

• The tumor microenvironment (TME) critically influences cancer immunotherapy outcomes.
• Current immunotherapies, such as checkpoint blockade, have limitations in efficacy for many patients.
• Modulating the TME is a promising strategy to enhance anti-cancer immune responses.

Purpose of the Study:

• To investigate the potential of synthetic biology to reprogram the TME for improved cancer immunotherapy.
• To assess the impact of engineered bacteria altering intratumoral arginine levels on anti-PD-L1 efficacy.
• To evaluate this strategy in a preclinical murine cancer model.

Main Methods:

• Utilized synthetic biology to engineer bacteria for modulating intratumoral arginine levels.
• Administered engineered bacteria to a murine cancer model.
• Assessed tumor growth and immune cell infiltration.
• Evaluated the response to anti-PD-L1 checkpoint blockade therapy.

Main Results:

• Engineered bacteria successfully altered intratumoral arginine concentrations within the TME.
• Increased arginine levels mediated by engineered bacteria enhanced the efficacy of anti-PD-L1 therapy.
• Observed improved anti-tumor immune responses and reduced tumor progression in treated mice.
• Demonstrated a synergistic effect between bacterial modulation of arginine and checkpoint blockade.

Conclusions:

• Reprogramming the TME via synthetic biology and engineered bacteria is a viable strategy to boost cancer immunotherapy.
• Targeting intratumoral arginine metabolism presents a novel approach to overcome resistance to checkpoint inhibitors like anti-PD-L1.
• This study provides a proof-of-concept for microbiome-based engineering to enhance cancer treatment efficacy.